Pfizer Reports Results of 20vPnC in P-III Trial for the Prevention of Invasive Pneumococcal Disease
- The P-III study evaluated the tolerability, safety & immunogenicity of 20vPnC vs Prevnar 13 in infants vaccinated at age 2/4/6/12-15mos. across the US for the prevention of invasive pneumococcal disease caused by the 20 Streptococcus pneumoniae serotypes in vaccines
- The two co-primary objectives of the study were NI of the percentage of participants with predefined serotype-specific IgG concentrations after the 3rd dose & Ni of IgG GMCs after the 4th dose. All 20 serotypes met the co-primary objective of NI after the 4th dose, 14 met NI after the 3rd dose, whereas all serotypes met the NI secondary objective of IgG GMCs after the 3rd dose
- Pfizer plans to submit an sBLA based on the positive safety & immunogenicity data by the end of 2022 along with the results from the clinical trial expected to be read out by the H2’22
Ref: Businesswire | Image: Pfizer
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.